BioMEL - a Translational Study About Aetiology, Diagnosis, Prognosis, Treatment, Biology and Biomarkers in Clinically Atypical Nevi and Melanoma.

What this Trial Is About

Researchers are exploring the differences in clinical, molecular, and genetic features among cutaneous melanoma, melanoma in situ, dysplastic nevi, and benign nevi. The study also seeks to understand biological aggressiveness and find objective diagnostic markers for both primary and secondary melanoma. It includes patients suspected of having primary melanoma or metastatic melanoma and collects detailed information to support this research. Participants are adults receiving routine dermatological, surgical, or oncological care who are scheduled for surgical excision or cytological diagnostics of pigmented skin lesions or metastatic melanoma. Before surgery, imaging and blood samples are collected. During surgery, skin punch biopsies of the lesion and nearby normal skin are taken and stored frozen. Tissue samples from metastatic melanoma are also collected through biopsies during treatment and follow-up. Participants complete questionnaires about risk factors, medical history, lifestyle, and quality of life. Researchers document lesions with imaging and collect histology and molecular data stored securely. The study measures genomic and transcriptomic differences across melanoma types and tracks these findings over time. The total participation period spans from initial inclusion through follow-up, with samples and data collected before, during, and after treatments.

BioMEL- Diagnostic and Prognostic Factors in Melanoma.